The Biotechpharma project plans to develop R & D infrastructure for the development and development of monoclonal antibodies of a specific glycosylation profile for the treatment of cancer. During the project, it is planned to develop a radically new technology for the production of monoclonal antibodies in SP2/0 cells (which are currently not highly productive in the world). The new technology will have a particularly high productivity compared to the original production technology. This will make it possible to produce significantly larger amounts of antibody, lower its cost, allow it to produce large quantities in a short period of time to further develop the indications and tests for the application of this antibody, and to expand the application of the antibody in clinical practice. In later stages of R & D activities, with the infrastructure created during the project, it is planned to develop and develop the production of other similar antibodies (antibodies for other cancers, autoimmune and neurodegenerative diseases). This would allow the company to expand its portfolio of products and services, successfully commercialise R & D results and become a competitive global biopharmaceutical company.